early resistance to pathogens; (ii) Th2 cells, which stimulate antibodymediated responses and promote immune tolerance rather than defend against microbial infection; (iii) regulatory T (Treg) cells, which suppress immune activity; and (iv) Th17 cells, which are important in the clearance of extracellular bacteria through IL-17A production. [20] [21] [22] [23] Th17 cells generate proinflammatory cytokines including IL-17A, IL-22, IL-26, tumor necrosis factor-α (TNF-α), chemokine (C-C motif) ligand 20 (CCL20), 24 and granulocyte macrophage colony-stimulating factor (GM-CSF). 11, 25 Differentiation of Th17 cells from naïve T cells is stimulated by proinflammatory cytokines, including IL-1β, IL-6, IL-21, and IL-23, in coordination with transforming growth factor-β (TGF-β) in a RAR-related orphan receptor-γ t (RORγt)-dependent manner. 11, [26] [27] [28] [29] Whereas RORγt triggers the development of Th17 cells and
IL-23 induces their maturation and expansion, TGF-β promotes Th17
cell differentiation in a dose-dependent manner. 11 At low concentrations TGF-β activates RORγt expression and Th17 differentiation, while high TGF-β concentrations stimulate forkhead box P3 (FOXP3) and Treg formation. 11, 30 Because of their opposing immune responses, the Th17/Treg balance is crucial for maintaining immune homeostasis. However, in extreme inflammatory or infectious conditions, the formation of Treg lymphocytes can become defective, thereby permitting these cells to phenotypically transform into Th17-like cells 3, 31, 32 through a process referred to as plasticity or transdifferentiation. 28 The clinical importance of Th17 cells is apparent in preterm neonates with chorioamnionitis exposure. Chorioamnionitis is a pathologic state of inflammation of the fetal membranes and is associated with increased cord blood quantities of IL-17A-producing Th17 lymphocytes 33 and Tregs that exhibit Th17-like phenotypes. 4 
| THE ROLE OF IL-17 IN NEONATAL SEPSIS
The capacity for the host to respond to sepsis is strongly influenced by the patient's developmental age. [71] [72] [73] [74] [75] [76] It is commonly accepted that IL-17A is important for neonatal host defense and protective immunity.
Physiologic levels of IL-17A produced by type 3 innate lymphoid cells (ILCs) improved resistance to infectious challenge in healthy neonatal mice via microbiota-driven granulocyte colony-stimulating factor (G-CSF) production and neutrophil recruitment. whereas altered production can injure developing lung tissue resulting in detrimental pulmonary pathologies in our youngest patients.
| THE ROLE OF IL-17 IN NECROTIZING ENTEROCOLITIS
Necrotizing enterocolitis is a life-threatening gastrointestinal ailment that affects up to 5% of all VLBW infants admitted to the neonatal intensive care unit. 110 Devastatingly, 10%-50% of neonates diagnosed with NEC will succumb to their illness, while one-third will suffer debilitating long-term complications, such as short-gut syndrome.
111
NEC onset is epidemiologically linked to a "window of susceptibility" with symptoms typically occurring in VLBW infants around 30-32 weeks of corrected gestational age (GA). Therefore, the youngest gestational-aged neonates will develop disease later in life than those who are older at birth. 112, 113 Because the incidence of NEC is also inversely proportional to GA at birth, 114 immature host defenses are thought to contribute to its pathogenesis. 115 Heightened baseline expression of Toll-like receptor (TLR)-4 and STAT3 in the intestinal mucosa of premature compared to full-term neonates, 116, 117 in addition to changes in microbial colonization and maturation of immune responses have been implicated in this association.
115,118
Immune homeostasis in the gut is normally maintained by the production of low levels of IL-17A by resident Th17 lymphocytes and
ILCs. 119 Secretion of IL-17A is influenced by the release of IL-1β and TGF-β from intestinal epithelial cells and functions to inhibit excessive bacterial growth in the gastrointestinal tract. 
| THE ROLE OF IL-1IN RETINOPATHY OF PREMATURITY
Retinopathy of prematurity is a common, biphasic vasoproliferative disorder of the developing retina that occurs in VLBW, critically ill, and severely growth-restricted infants. 124 ROP consists of initial blunting of retinal vascular growth followed by retinal vessel proliferation around 4-6 weeks of age. 49, 124, [128] [129] [130] [131] This abnormal growth is the hallmark of ROP and can be attenuated in murine models by IL-17A
neutralizing antibodies through modulation of the VEGF pathway.
132
In knockout models of IL-17A, inflammation was also alleviated and tissue repair facilitated by biasing macrophage polarization toward a M2 phenotype. This macrophage transformation leads to the production of high levels of IL-10, which dampens proinflammatory responses to enable wound healing. [132] [133] [134] [135] In contrast, IL-17 drives macrophage differentiation toward a M1 subtype, facilitating secretion of TNF-α, IL-1β, and IL-6 to enhance pro-angiogenic VEGF pathways and ROP.
Currently, anti-VEGF agents are routinely used to treat vasoproliferative diseases, including ROP. 136 However, a substantial number of eyes do not respond adequately to these specific therapies.
124,137-139
Development of innovative therapies based on IL-17A neutralization may be an effective treatment for ROP by attenuating microglial cell density, Müller cell gliosis, and ganglion cell loss.
124

| THE ROLE OF IL-17 IN THE PATENT DUCTUS ARTERIOSUS
The ductus arteriosus (ductus; PDA) is vital to the fetus allowing blood to be shunted away from the fetal lungs and into the systemic circulation. In term infants, the ductus constricts after birth due to an increase in tissue oxygenation and decreased levels of prostaglandin. 140, 141 The internal layer of the ductus becomes hypoxic with ductal constriction leading to neointimal cushion formation and extensive vascular remodeling. 140, 141 concentration at physiologic levels may promote vascular remodeling and platelet aggregation assisting ductal closure. However, the concentration at higher levels may induce pathologic ductal dilation due to its effect on prostaglandin production which could be the etiology of inflammatory-associated symptomatic PDA. Thus, therapeutic approaches that target attenuation of pathologic IL-17 production require further study prior to implementation in the preterm population.
| PHARMACOLOGIC INTERVENTIONS TARGETING IL-17 PATHWAYS
Presently, 2 monoclonal antibodies directed against IL-17A and one against the IL-17A receptor have completed phase III human trials.
These agents include the following: (i) Ixekizumab (LY2439821), a humanized IL-17A-specific antibody; (ii) Secukinumab (AIN457), a fully human IL-17A-specific antibody
152
; and (iii) Brodalumab (AMG 827),
an IL-17A-specific antibody. 152 Because the inhibition of IL-17A may increase the risks of extracellular bacterial 153 and/or fungal infections, careful attention must be paid when this cytokine is specifically targeted. 152 Adult and animal studies provide important information as we ponder the use of these therapies in neonatal patients. However, our understanding of IL-17A pathways in term and preterm infants remains incomplete and is a barrier to clinical trials that target IL-17 signaling in this unique population. 
| CONCLUSION
